-
Revenue: Dropped to $0.8 million in 2023 from $44.7 million in 2022, primarily due to decreased Vaxzevria sales.
-
Net Loss: Expanded to $73.3 million, or $1.91 per share, reversing the prior year’s net income of $5.3 million, or $0.14 per share.
-
Cash Position: Decreased to $142.1 million at year-end 2023 from $194.4 million at the end of 2022.
-
R&D Expenses: Increased slightly to $44.9 million, reflecting ongoing clinical trials and pipeline development.
-
General and Administrative Expenses: Rose significantly to $39.8 million, largely due to foreign exchange losses.
Barinthus Biotherapeutics PLC (NASDAQ:BRNS) released its 8-K filing on March 20, 2024, detailing its financial outcomes for the year ended December 31, 2023. The clinical-stage biopharmaceutical company, known for its innovative T cell immunotherapeutic candidates aimed at tackling chronic infectious diseases, autoimmunity, and…
